Overview
Telmisartan Tab Hypertension
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular riskAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Boehringer IngelheimTreatments:
Hydrochlorothiazide
Telmisartan
Telmisartan, hydrochlorothiazide drug combination
Criteria
Inclusion criteria:Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk
according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision
to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12.5 mg or 25 mg, in
the usual way and in line with the SmPC and reimbursement criteria
Exclusion criteria:
Contra-indications as in the Summary of Product Characteristics